#5-71E. Redefining PMR and Large Vessel Vasculitis Management: The 2025 EULAR Consensus (Ann Rheum Dis, 2026)

How should clinicians navigate glucocorticoid-sparing strategies and emerging biologics in polymyalgia rheumatica and large vessel vasculitis? The updated EULAR recommendations unify guidance for polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis, endorsing novel targeted therapies like upadacitinib and sarilumab to achieve glucocorticoid-free remission. However, evidence for these newer targeted agents relies heavily on single phase-3 trials, lacking long-term safety data and head-to-head comparative studies. This comprehensive consensus provides physicians with practical algorithms to optimize rapid diagnosis, tailored tapering, and steroid-sparing interventions in routine practice.

Citation: Chetan B. Mukhtyar, et al. 2025 EULAR recommendations for the management of polymyalgia rheumatica and primary large vessel vasculitis. Annals of the Rheumatic Diseases. 2026.DOI: 10.1016/j.ard.2026.06.009

URL: https://doi.org/10.1016/j.ard.2026.06.009

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.